MAPT and Alzheimer disease: CMA is downregulated in AD patient brains [254]; CMA upregulation improves the disease phenotype that results from MAPT or combined MAPT and Aβ pathologies, and inhibition of CMA accelerates the AD pathology in a mouse model [254].